Sökresultat - "Recurrence"

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Horwitz SM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Feldman TA; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA., Ye JC; University of Michigan, Ann Arbor, MI, USA., Khodadoust MS; Stanford University School of Medicine, Palo Alto, CA, USA., Munoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Hamlin PA; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kim YH; Stanford University School of Medicine, Palo Alto, CA, USA., Wilcox RA; University of Michigan, Ann Arbor, MI, USA., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Coffey G; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Innes A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Betz A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Holland J; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Guzman CB; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Smith SM; University of Chicago Medicine, Chicago, IL, USA.

Journal Article; Clinical Trial, Phase II; Multicenter Study , 2025

Impact of sella floor reconstruction on Rathke Cleft Cyst recurrence: a systematic review and meta-analysis.

Dolovac RB; School of Medicine, University of Western Australia, Perth, Australia., King J; Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, Australia.; Department of Surgery, University of Melbourne, Melbourne, Australia., Ovenden C; Department of Neurosurgery, Royal Adelaide Hospital, Adelaide, Australia.; Faculty of Health and Medical Sciences, Adelaide Medical School, Adelaide, Australia., Kam J; Department of Neurosurgery, Monash Health, Melbourne, Australia.; Department of Surgery, Monash University, Melbourne, Australia., Wang YY; Department of Neurosurgery, St Vincent's Health, Melbourne, Australia.; Department of Surgery, University of Melbourne, Melbourne, Australia., Goldschlager T; Department of Neurosurgery, Monash Health, Melbourne, Australia.; Department of Surgery, Monash University, Melbourne, Australia., Castle-Kirszbaum M; Department of Neurosurgery, Monash Health, Melbourne, Australia. mdck.journal@gmail.com.; Department of Surgery, Monash University, Melbourne, Australia. mdck.journal@gmail.com.

Journal Article; Systematic Review; Meta-Analysis; Review , 2025

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.

Oliai C; Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Park S; Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Damon LE; Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA., Jonas BA; Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, CA, USA., Jeyakumar D; Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, School of Medicine, Orange, CA, USA., Wieduwilt MJ; Department of Internal Medicine, Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Logan AC; Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA., Callas B; Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Hannigan CA; Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Gaut DL; Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Schiller GJ; Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.

Journal Article; Multicenter Study; Clinical Trial, Phase I , 2025

Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma.

Wang H; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Wang G; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Li T; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Zhang P; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Mao Z; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Luo H; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Zhu X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Li D; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China., Zhou X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. cello316@tjh.tjmu.edu.cn., Huang L; State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300020, China. huangliang@ihcams.ac.cn.; Tianjin Institutes of Health Science, Tianjin, 301600, China. huangliang@ihcams.ac.cn.

Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I , 2025

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.

An N; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Li J; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Luo P; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Wang D; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Zhang P; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Shu C; Office of Drug Clinical Trial, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China., Cai S; Nanjing IASO Biotherapeutics Ltd, Shanghai, China., Yu Q; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Wen X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Wang X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Mu W; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Hu J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China., Li C; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, P. R. China. cunrui5650@hust.edu.cn.; Key Laboratory of Vascular Aging, Tongji Hospital, Tongji Medical College, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. cunrui5650@hust.edu.cn.; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China. cunrui5650@hust.edu.cn.

Journal Article; Observational Study , 2025

Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review.

Ludwig H; Wilhelminen Cancer Research Institute, Vienna, Austria., Bernhard S; Wilhelminen Cancer Research Institute, Vienna, Austria., Ikeda T; Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan., Freytes CO; University of Texas Health Science Center San Antonio, San Antonio, Texas, USA., Schreder M; Department of Medicine I, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria., Kawamura K; Hematology, Tottori University Hospital, Yonago, Japan., Atsuta Y; Japanese Data Center For Hematopoietic Cell Transplantation, Nagakute, Japan., Takamatsu H; Kanazawa University, Kanazawa, Ishikawa, Japan., Vesole DH; Myeloma Division, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA., Hari P; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Krainer J; Wilhelminen Cancer Research Institute, Vienna, Austria., Hinke A; Cancer Clinical Research Consulting, Düsseldorf, Germany.

Journal Article; Systematic Review; Comparative Study; Meta-Analysis , 2025

Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study.

Zhen J; Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Lai S; Department of Hematology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China., Zhang X; Department of Hematology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Huang L; Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Li P; Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Lin Y; Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Xu D; Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: Duorong1014@126.com., He G; Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: louise.henry@126.com.

Journal Article; Multicenter Study , 2025

The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma.

Kim K; Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA., Chihara D; Department of Lymphoma-Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.

Journal Article; Review , 2025

Diuresis During ¹⁸ F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.

Lawal IO; Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia; ilawal@emory.edu.; Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa., Mushtaq A; Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia., Jani AB; Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Rupji M; Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia., Dhere VR; Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Patel SA; Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Bilen MA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia; and., Patel PR; Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Sebastian NT; Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Switchenko JM; Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia., Schuster DM; Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia., Marcus C; Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

Journal Article; Clinical Trial, Phase II , 2025

Borderline Findings in O -(2-[ ¹⁸ F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.

Langen KJ; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany; k.j.langen@fz-juelich.de.; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.; Center of Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Germany., Stoffels G; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany., Filss CP; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., Kocher M; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.; Department of Stereotaxy and Functional Neurosurgery, Center for Neurosurgery, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Lerche C; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany., Sabel M; Center of Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Germany.; Department of Neurosurgery, University of Duesseldorf, Duesseldorf, Germany., Rapp M; Center of Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Germany.; Department of Neurosurgery, University of Duesseldorf, Duesseldorf, Germany., Noltemeier H; Department of Neurosurgery, University of Duesseldorf, Duesseldorf, Germany., Werner JM; Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Ceccon G; Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Wollring MM; Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Rosen J; Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Steinbach JP; University Cancer Center Frankfurt, Goethe University Hospital, Frankfurt am Main, Germany.; Dr. Senckenberg Institute of Neurooncology, Goethe University Frankfurt, Frankfurt am Main, Germany., Hattingen E; University Cancer Center Frankfurt, Goethe University Hospital, Frankfurt am Main, Germany.; Institute of Neuroradiology, Goethe University Hospital, Frankfurt am Main, Germany., Weinzierl MR; Department of Neurosurgery, Helios Clinics Krefeld, Krefeld, Germany., Stoffel M; Department of Neurosurgery, Helios Clinics Krefeld, Krefeld, Germany., Clusmann H; Department of Neurosurgery, University Hospital RWTH Aachen, Aachen, Germany., Shah NJ; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.; JARA-BRAIN-Translational Medicine, Aachen, Germany.; Department of Neurology, RWTH Aachen University, Aachen, Germany; and., Mottaghy FM; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.; Center of Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Germany.; JARA-BRAIN-Translational Medicine, Aachen, Germany.; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands., Galldiks N; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.; Center of Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Germany.; Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Lohmann P; Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.

Journal Article , 2025

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.

Singal AG; University of Texas Southwestern, Dallas, Texas, USA., Reddy KR; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Colombo M; Humanitas Hospital, Rossano, Italy., Morris HL; Target RWE, Durham, North Carolina, USA., Mospan AR; Target RWE, Durham, North Carolina, USA., Cabrera R; University of Florida, Gainesville, Florida, USA., Kelley RK; University of California san Francisco, San Francisco, California, USA., Kilpatrick RD; AbbVie, Chicago, Illinois, USA., Trevisani F; Italian Liver Cancer (ITA.LI.CA) Association, Bologna, Italy., Farinati F; Padua University, Padua, Italy., Giannini EG; Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino University of Genoa Viale Benedetto XV, Genoa, Italy., Mehta N; University of California san Francisco, San Francisco, California, USA., Fried MW; Target RWE, Durham, North Carolina, USA., Sangro B; Clinica Universidad de Navarra, Pamplona, Spain.

DAA‐PASS and ITA.LI.CA Investigators

Journal Article; Observational Study , 2025

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.

Cohen YC; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Magen H; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Gatt M; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Sebag M; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Kim K; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Min CK; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Ocio EM; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Yoon SS; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Chu MP; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Rodríguez-Otero P; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Avivi I; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Quijano Cardé NA; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Kumar A; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Krevvata M; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Peterson MR; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Di Scala L; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Scott E; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Hilder B; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Vanak J; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Banerjee A; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Oriol A; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Morillo D; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.)., Mateos MV; From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew University Medical Center, Jerusalem (M.G.) - all in Israel; McGill University and McGill University Health Centre, Montreal (M.S.), and Alberta Health Services, Edmonton (M.P.C.) - all in Canada; Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), Seoul St. Mary's Hospital, Catholic University of Korea (C.-K.M.), and Seoul National University College of Medicine (S.-S.Y.) - all in Seoul, South Korea; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Universidad de Cantabria, Santander (E.M.O.), Cancer Center Clínica Universidad de Navarra, Center for Applied Medical Research, Pamplona (P.R.-O.), Institut Català d'Oncologia, Josep Carreras Leukemia Research Institute, and the Hospital Germans Trias i Pujol, Barcelona (A.O.), START Madrid-Fundación Jiménez Díaz Early Phase Unit, University Hospital Fundación Jiménez Díaz, Madrid (D.M.), and the University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, the Salamanca Cancer Research Center, and Centro de Investígación Biomédica en Red Cáncer, Salamanca (M.-V.M.) - all in Spain; Janssen Research and Development, Spring House, PA (N.A.Q.C., A.K., M.K., M.R.P., E.S., B.H., J.V., A.B.); and Janssen Research and Development, Allschwil, Switzerland (L.D.S.).

RedirecTT-1 Investigators and Study Group

Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study , 2025

Nutritional status at diagnosis and its relationship with survival and relapse in Mexican children with acute lymphoblastic leukemia: a retrospective study.

Guzmán-León AE; Department of Chemical and Biological Sciences, Universidad de Sonora, Hermosillo, Sonora, Mexico., Gallegos-Castorena S; Pediatric Hemato-Oncology Service, Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca', Guadalajara, Jalisco, Mexico., Romo-Rubio H; Pediatric Hemato-Oncology Service, Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca', Guadalajara, Jalisco, Mexico., Casillas-Toral E; Casa de La Amistad Para Niños Con Cáncer, Mexico City, Mexico., Lopez-Teros V; Department of Chemical and Biological Sciences, Universidad de Sonora, Hermosillo, Sonora, Mexico., Stein K; Pediatric Hemato-Oncology Service, Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca', Guadalajara, Jalisco, Mexico. katja2mx2004@hotmail.com.; Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Salvador Quevedo y Zubieta 750, Independencia Oriente, Guadalajara, Jalisco, 44360, Mexico. katja2mx2004@hotmail.com.

Journal Article; Observational Study , 2025

Treatment of relapsed/refractory MCL.

Silkenstedt E; Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany., Dreyling M; Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany.

Journal Article; Review , 2025

Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis.

Okcu I; Division of Hematology, Mayo Clinic, Rochester, MN., Wang Y; Division of Hematology, Mayo Clinic, Rochester, MN., Bock AM; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Zhou J; Department of Hematology, Shenzhen People's Hospital, Shenzhen, China., Moustafa MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL., Tun HW; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL., Rosenthal AC; Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ., Johnston PB; Division of Hematology, Mayo Clinic, Rochester, MN., Baidoun F; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL., Khurana A; Division of Hematology, Mayo Clinic, Rochester, MN., Kabat BF; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., King RL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: Nowakowski.grzegorz@mayo.edu.

Journal Article , 2025

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma.

Zhang R; Department of Hematology, Tianjin First Central Hospital, Tianjin, China., Zhang Y; Department of Hematology, First Center Clinic College of Tianjin Medical University, Tianjin, China., Xiao H; Boyalife wsn ltd, Shen Zhen, China., Liu Q; Boyalife wsn ltd, Shen Zhen, China. liuqingxi66@aliyun.com., Zhao M; Department of Hematology, Tianjin First Central Hospital, Tianjin, China. mingfengzhao@sina.com.; Department of Hematology, First Center Clinic College of Tianjin Medical University, Tianjin, China. mingfengzhao@sina.com.

Journal Article , 2025

How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma.

Wallace DS; Division of Hematology/Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Loh KP; Division of Hematology/Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Casulo C; Division of Hematology/Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

Journal Article; Review; Case Reports , 2025

Dynamic Relapse Prediction by Peripheral Blood WT1mRNA after Allogeneic Hematopoietic Cell Transplantation for Myeloid Neoplasms.

Nakako S; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Okamura H; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Electronic address: h_okamura@omu.ac.jp., Yokota I; Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan., Umemoto Y; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Horiuchi M; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Sakatoku K; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Ido K; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Makuuchi Y; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Kuno M; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Takakuwa T; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Nishimoto M; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Hirose A; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Nakamae M; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Nakashima Y; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Koh H; Department of Preventive Medicine and Environmental Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Hino M; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan., Nakamae H; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Journal Article , 2024

Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis.

Stankiewicz J; Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland; joanna.konieczek@cm.umk.pl., Jabłońska A; Student Scientific Society, Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland., Treichel P; Student Scientific Society, Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland., Demidowicz E; Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland., Styczyński J; Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.

Journal Article , 2024

Multi-modal fusion and feature enhancement U-Net coupling with stem cell niches proximity estimation for voxel-wise GBM recurrence prediction ^.

Jiao C; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Lao Y; Department of Radiation Oncology, UC Los Angeles, Los Angeles, CA 90095, United States of America., Zhang W; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Braunstein S; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Salans M; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Villanueva-Meyer J; Department of Radiology and Biomedical Imaging, UC San Francisco, San Francisco, CA 94143, United States of America., Hervey-Jumper SL; Department of Neurosurgery, UC San Francisco, San Francisco, CA 94143, United States of America., Yang B; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Morin O; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Valdes G; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Fan Z; Department of Radiology, University of Southern California, Los Angeles, CA 90033, United States of America., Shiroishi M; Department of Radiology, University of Southern California, Los Angeles, CA 90033, United States of America., Zada G; Department of Neurosurgery, University of Southern California, Los Angeles, CA 90033, United States of America., Sheng K; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America., Yang W; Department of Radiation Oncology, UC San Francisco, San Francisco, CA 94143, United States of America.

Journal Article , 2024